BioCryst Pharmaceuticals (MEX:BCRX) Cyclically Adjusted Book per Share: MXN-13.48 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BCRX BioCryst Pharmaceuticals Inc MEX:BCRX
63 GF Score
Price MXN182.00
GF Value MXN216.86
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioCryst Pharmaceuticals Cyclically Adjusted Book per Share?

BioCryst Pharmaceuticals MEX:BCRX 63 Cyclically Adjusted Book per Share is MXN-13.48 as of Jun. 2026. GuruFocus rates MEX:BCRX with a GF Score™ of 63/100 and a GF Value™ of MXN216.86 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

BioCryst Pharmaceuticals's adjusted book value per share for the three months ended in Jun. 2026 was MXN-31.054. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN-13.48 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of BioCryst Pharmaceuticals was 0.70% per year. The lowest was -71.90% per year. And the median was -10.85% per year.

As of today (2026-08-19), BioCryst Pharmaceuticals's current stock price is MXN182.00. BioCryst Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was MXN-13.48. BioCryst Pharmaceuticals's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BioCryst Pharmaceuticals was 635.00. The lowest was 2.54. And the median was 10.26.


BioCryst Pharmaceuticals  (MEX:BCRX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BioCryst Pharmaceuticals was 635.00. The lowest was 2.54. And the median was 10.26.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


BioCryst Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


BioCryst Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for BioCryst Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCryst Pharmaceuticals Cyclically Adjusted Book per Share Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.08 3.75 0.19 -7.01 -12.88

BioCryst Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.24 -12.40 -12.88 -12.60 -13.48

MEX:BCRX vs PBH, SUPN, AMLX: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


MEX:BCRX
63GF Score
BioCryst Pharmaceuticals Inc MEX:BCRX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCryst Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioCryst Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-31.054/333.9520*333.9520
=-31.054

Current CPI (Jun. 2026) = 333.9520.

BioCryst Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 1.047 241.428 1.448
201612 0.441 241.432 0.610
201703 9.026 243.801 12.364
201706 5.411 244.955 7.377
201709 18.562 246.819 25.115
201712 16.717 246.524 22.646
201803 11.422 249.554 15.285
201806 9.173 251.989 12.157
201809 12.434 252.439 16.449
201812 8.783 251.233 11.675
201903 3.959 254.202 5.201
201906 -1.600 256.143 -2.086
201909 -7.374 256.759 -9.591
201912 4.682 256.974 6.085
202003 0.555 258.115 0.718
202006 10.009 257.797 12.966
202009 4.208 260.280 5.399
202012 -2.166 260.474 -2.777
202103 -8.627 264.877 -10.877
202106 -11.814 271.696 -14.521
202109 -16.817 274.310 -20.473
202112 -11.905 278.802 -14.260
202203 -17.619 287.504 -20.465
202206 -23.079 296.311 -26.011
202209 -26.185 296.808 -29.462
202212 -30.566 296.797 -34.392
202303 -31.328 301.836 -34.661
202306 -35.168 305.109 -38.493
202309 -37.718 307.789 -40.924
202312 -37.577 306.746 -40.910
202403 -38.298 312.332 -40.949
202406 -42.168 314.175 -44.822
202409 -44.545 315.301 -47.180
202412 -47.597 315.605 -50.364
202503 -44.193 319.799 -46.149
202506 -37.818 322.561 -39.154
202509 -33.799 324.800 -34.751
202512 -10.070 324.054 -10.378
202603 -39.318 330.213 -39.763
202606 -31.054 333.952 -31.054

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of MXN-13.48 mean?
BioCryst Pharmaceuticals (MEX:BCRX) has a Cyclically Adjusted Book per Share of MXN-13.48 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BioCryst Pharmaceuticals and its competitors.
Is BioCryst Pharmaceuticals' Cyclically Adjusted Book per Share too high?
BioCryst Pharmaceuticals' current Cyclically Adjusted Book per Share is MXN-13.48. Overall, BioCryst Pharmaceuticals has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' Cyclically Adjusted Book per Share compare to PBH and SUPN?
BioCryst Pharmaceuticals' Cyclically Adjusted Book per Share of MXN-13.48 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BioCryst Pharmaceuticals and its competitors. BioCryst Pharmaceuticals's current Cyclically Adjusted Book per Share is MXN-13.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (MEX:BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN216.86, compared to a current price of MXN182.00 — trading 16.1% below its estimated fair value. The current Cyclically Adjusted Book per Share is MXN-13.48. BioCryst Pharmaceuticals' overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For BioCryst Pharmaceuticals (MEX:BCRX), the current Cyclically Adjusted Book per Share is MXN-13.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioCryst Pharmaceuticals (MEX:BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of MXN182.00 is trading 16.1% below its estimated GF Value™ of MXN216.86. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for MEX:BCRX:

  • Cyclically Adjusted Book per Share: MXN-13.48
  • GF Value™: MXN216.86 vs. price of MXN182.00 (16.1% below fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the MEX:BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioCryst Pharmaceuticals Business Description

Other Exchanges BCRX:USABO1:Germany
Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
63GF Score

Get the complete analysis for MEX:BCRX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN182.00
Price
MXN216.86
GF Value